Chromogranin A (CgA) and Pancreastatin (PcSt) as Predictors of Peptide Receptor Radionuclide Therapy (PRRT) Outcomes in Patients with Metastatic Well-Differentiated Neuroendocrine Tumors (mNETs)

#439

Introduction: CgA and PcSt are widely used in assessing response to treatment in mNETs.

Aim(s): To study the role of pre PRRT levels of CgA and PcSt on overall survival (OS) and median time to progression (mTTP).

Materials and methods: One-hundred and thirty-five cases from the University of Iowa NET database were analyzed and survival calculated.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Sharma N, Naraev B, Engelman E, Zimmerman M, Bushnell D,

Keywords: pancreastatin, chromogranin, peptide, receptor, radionuclide, therapy, PRRT, neuroendocrine, tumors,